Free Trial
NASDAQ:CCCC

C4 Therapeutics Q3 2024 Earnings Report

C4 Therapeutics logo
$1.25 +0.15 (+13.64%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$1.22 -0.03 (-2.40%)
As of 04/17/2025 06:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

C4 Therapeutics EPS Results

Actual EPS
-$0.35
Consensus EPS
-$0.40
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

C4 Therapeutics Revenue Results

Actual Revenue
$15.36 million
Expected Revenue
$5.95 million
Beat/Miss
Beat by +$9.41 million
YoY Revenue Growth
N/A

C4 Therapeutics Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Thursday, October 31, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

C4 Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled on Friday, May 2, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

C4 Therapeutics Earnings Headlines

The Crypto Market is About to Change Lives
I've discovered something so significant about the 2025 crypto market that I had to put everything else aside and write a book about it. This isn't just another Bitcoin prediction – it's a complete roadmap for what I believe will be the biggest wealth-building opportunity of this decade. The evidence is so compelling, I'm doing something that probably seems insane: I'm giving away my entire book for free.
Stifel Nicolaus Reaffirms Their Buy Rating on C4 Therapeutics (CCCC)
See More C4 Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like C4 Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on C4 Therapeutics and other key companies, straight to your email.

About C4 Therapeutics

C4 Therapeutics (NASDAQ:CCCC), a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

View C4 Therapeutics Profile

More Earnings Resources from MarketBeat